Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinica BavieraXMAD:CBAV -3.73%100 3-Year EPS without NRI Growth Rate is 12.30% as of Jun. 2026, which is 2% below its 10-year median of 12.55. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €44.61 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 50.62% on this metric.
During the past 12 months, Clinica Baviera's average EPS without NRI Growth Rate was 17.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 12.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 21.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Clinica Baviera was 38.50% per year. The lowest was -46.50% per year. And the median was 12.55% per year.
Clinica Baviera (XMAD:CBAV) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Clinica Baviera 3-Year EPS without NRI Growth Rate Related Terms
XMAD:CBAV vs TMO, DHR, NTRA: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's 3-Year EPS without NRI Growth Rate falls into.
Clinica Baviera 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 12.30% mean?
Clinica Baviera (XMAD:CBAV) has a 3-Year EPS without NRI Growth Rate of 12.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Clinica Baviera and its competitors. This is near median its historical median of 12.55. According to the industry distribution chart, Clinica Baviera ranks #79 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 49.4%.
Is Clinica Baviera's 3-Year EPS without NRI Growth Rate too high?
Clinica Baviera's current 3-Year EPS without NRI Growth Rate of 12.30% is near median its 10-year median of 12.55. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 11.85. Clinica Baviera's value of 12.30% is 3.8% above this industry median. Based on the distribution chart, Clinica Baviera ranks #79 out of 160 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #79 out of 160 companies for 3-Year EPS without NRI Growth Rate. This puts Clinica Baviera in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.85. Clinica Baviera's value of 12.30% is 3.8% above this benchmark. While the company's 10-year median is 12.55 vs. the industry median of 11.85, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 11.85, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current 3-Year EPS without NRI Growth Rate of 12.30% is 3.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 11.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current 3-Year EPS without NRI Growth Rate is 12.30%, which is near median its own 10-year median of 12.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.61, compared to a current price of €56.80 — trading 27.3% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 12.30%, which is near median its 10-year median of 12.55 and 3.8% above the Medical Diagnostics & Research industry median of 11.85. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current 3-Year EPS without NRI Growth Rate is 12.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.80 is trading 27.3% above its estimated GF Value™ of €44.61.
GuruFocus considers Clinica Baviera to be Modestly Overvalued.
Key valuation signals for XMAD:CBAV:
3-Year EPS without NRI Growth Rate: 12.30% (near median its 10-year median of 12.55)
GF Value™: €44.61 vs. price of €56.80 (27.3% above fair value)
Industry Position: 3.8% above the Medical Diagnostics & Research median (#79 of 160)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
